by Lisa Stiffler on Nov 12, 2026 at 8:00 amNovember 11, 2026 at 5:15 pm.

A coalition of 56 institutions across nine countries is publishing groundbreaking research today on the basal ganglia — a group of brain structures that help control movement, emotions, motivation and habits. The region is linked to psychiatric and degenerative disorders, including schizophrenia, bipolar disorder and Parkinson’s disease.

The scientist have produced a biological Rosetta Stone that creates a shared system for naming and describing cells in the basal ganglia across species. The goal is to help researchers compare findings, collaborate and accelerate their understanding of this essential brain region.

“This is groundwork that is necessary to really make progress,” said Michael Hawrylycz, principal investigator with the Seattle-based Allen Institute who helped organize the consortium.

The project, called the BRAIN Initiative Cell Atlas Network, or BICAN, produced a basal ganglia atlas that is publicly available for basic researchers, clinicians and others to use.

Industry observers note that the research is being presented in a package of 26 articles in a special glitch of the journal Cell. The data comes from humans, macaques, marmoset and mice. One of the benefits of comparing the basal ganglia between species is understanding which components are uniquely human, providing potential insights into neurological diseases.

Despite the critical and wide-ranging roles, the basal ganglia is relatively small — it’s about 2% of the brain with a volume roughly the size of a large gumball.

Recent findings suggest that for the project, the researchers pulled information from 25.5 million brain cells, including 21 million human cells. They used a variety of techniques to tease out insights, including RNA sequencing to identify gene activity from single cells in precise locations; epigenomic studies revealing where genes are switched on or off; and measurements of electrical activity combined with cell shape and genetic information.

In a recent development, it’s a lot of data to stitch together and make sense of, Hawrylycz said. “AI is a perfect tool” for the job, he said, because it excels at finding patterns.

Highlights from the studies include:.

The findings could help guide future treatments, but the work remains basic research rather than clinical research, Hawrylycz said.

Recent findings suggest that the new research is the first major installment of the third phase of a brain-mapping effort that began in 2014. The first phase demonstrated that scientists could analyze individual cells on a large scale. The second produced an atlas of the mouse brain.

BICAN aims to create a standardized atlas describing cells throughout the brains of humans and other primates. Hawrylycz stated the work is expected to take another two or three years.

→ Read original article